MedTrace Logo

CYP2B6 Polymorphisms in Ketamine

NCT01988922 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-05-18

Study results available
· View outcomes & findings →

Summary

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ketamine

0.4 mg/kg oral racemic ketamine

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Lesley Rao, MD · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01988922 on ClinicalTrials.gov